Stock Compensation (Tables)

9 Months Ended

Sep. 30, 2015

Total Compensation Cost from Share-Based Payments

The Company’s statements of operations included total compensation cost from awards under the plans and purchases under the ESPP for the three-month and nine-month periods ended September 30, 2015 and 2014, as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
In thousands	2015		2014		2015		2014
Compensation cost from:
Stock options	$	3,348	$	3,583	$	11,718	$	12,427
Stock and stock units		6,396		3,961		16,858		11,787
Purchases of common stock at a discount		187		94		433		369
	$	9,931	$	7,638	$	29,009	$	24,583
Compensation cost included in:
Research and development expenses	$	3,633	$	3,229	$	11,629	$	10,570
Selling, general and administrative expenses		6,298		4,409		17,380		14,013
	$	9,931	$	7,638	$	29,009	$	24,583

Stock Option Activity

Stock option activity under the Company’s stock plans for the nine-month period ended September 30, 2015 was as follows:

	Number of shares			Weighted Average Exercise Price Per Share
Options outstanding, January 1, 2015		10,148,087		$	10.09
Granted		1,095,500		$	7.87
Forfeited		(541,138	)	$	10.27
Exercised		(638,743	)	$	5.84
Options outstanding, September 30, 2015		10,063,706		$	10.11

Stock and Stock Unit Activity

Stock and stock unit activity under the Company’s stock plans for the nine-month period ended September 30, 2015 was as follows:

	Number of shares			Weighted Average Grant Date Fair Value
Stock units outstanding, January 1, 2015		3,503,153		$	9.97
Granted / awarded		3,003,375		$	8.70
Forfeited		(115,112	)	$	8.17
Vested or restrictions lapsed		(1,250,520	)	$	11.87
Stock units outstanding, September 30, 2015		5,140,896		$	8.81

Outstanding Performance Share Units Awarded

Included in the table above are outstanding performance share units which were awarded from 2012 to 2015 as noted below:

Years of Award	Number of Units		Description of Performance Metric
2013		158,000	Brigatinib clinical trial enrollment (100%) – achieved in 2015
2014		1,044,000	Iclusig clinical trial enrollment (50%); cumulative revenues from sales of Iclusig in 2014 and 2015 (50%)
2015		731,300	Iclusig clinical trial enrollment (315,000 units); 2015 revenues from sales of Iclusig (315,000 units); total relative return on common stock 2015-2017 (101,300 units)